Austrian biotech Marinomed said sales of its virus-blocking compound Carragelose had slumped to pre-pandemic levels as a three-year period of elevated demand came to an end.
“After SARS-CoV-2-driven record sales in the last years, the market is now suffering a pandemic overhang with high customer stock levels and the return of the typical volatile seasonality,” commented CEO Andreas Grassauer
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?